Menu
Search
|

Menu

Close
X

Astellas Pharma Inc 4503.T (Tokyo Stock Exchange)

1,527.00 JPY
+3.00 (+0.20%)
As of 6:00 AM GMT
chart
Previous Close 1,524.00
Open 1,517.00
Volume 6,211,100
3m Avg Volume 7,620,053
Today’s High 1,529.00
Today’s Low 1,511.00
52 Week High 1,570.00
52 Week Low 1,331.50
Shares Outstanding (mil) 2,068.82
Market Capitalization (mil) 3,012,207.00
Forward P/E 15.71
Dividend (Yield %) 18.00 ( 2.34 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.83 Mean rating from 12 analysts

KEY STATS

Revenue (mm, JPY)
FY18
999,443
FY17
1,311,665
FY16
1,372,706
FY15
1,247,259
EPS (JPY)
FY18
69.883
FY17
103.443
FY16
89.554
FY15
61.379
*Note: Units in Millions of Yen
**Note: Units in Yen

KEY RATIOS

Price to Earnings (TTM)
vs sector
15.71
32.90
Price to Sales (TTM)
vs sector
2.32
5.77
Price to Book (MRQ)
vs sector
2.28
5.41
Price to Cash Flow (TTM)
vs sector
11.66
23.42
Total Debt to Equity (MRQ)
vs sector
2.86
16.52
LT Debt to Equity (MRQ)
vs sector
2.56
12.22
Return on Investment (TTM)
vs sector
13.91
14.43
Return on Equity (TTM)
vs sector
15.50
16.13

EXECUTIVE LEADERSHIP

Yoshihiko Hatanaka
President, Chief Executive Officer, Representative Director, Since 2017
Salary: --
Bonus: --
Chikashi Takeda
Chief Financial Officer, Executive Officer, Since 2017
Salary: --
Bonus: --
Fumiaki Sakurai
Chief Administrative Officer, Chief Ethics & Compliance Officer, Executive Officer, Since 2017
Salary: --
Bonus: --
Kenji Yasukawa
Vice President, Chief Strategy Officer, Chief Commercial Officer, Representative Director, Since 2017
Salary: --
Bonus: --
Nate Crisel
Vice President - Real World Informatics & Analytics, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Astellas Pharma Inc. Headquarter
2-5-1, Nihombashihon-cho
CHUO-KU   TKY   103-8411

Phone: +813.32443000

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive bladder agent Vesicare, Protopic ointment for atopic dermatitis, Harnal for prostatic and urethral smooth muscle, and antimycotic agent Funguard, among others. It also provides pharmaceutical products for gastritis, osteoporosis, hypertension, schizophrenia, rheumatoid arthritis, atopic dermatitis and other diseases. The Company also engages in the research and development of ophthalmology pharmaceuticals through its subsidiaries.

SPONSORED STORIES